Della Porta G, Radice P, Pierotti M A
Division of Experimental Oncology A, Istituto Nazionale Tumori, Milan, Italy.
Tumori. 1989 Aug 31;75(4):329-36. doi: 10.1177/030089168907500406.
The analysis of the molecular mechanisms governing multistep carcinogenesis became experimentally approachable since the identification and characterization in tumor cells of altered or activated versions of cellular genes (oncogenes) that normally control cell growth and differentiation. The activating mutations confer new properties to the oncogene products and should therefore be considered as gain of function mutations. In addition, the oncogenes appear to act as dominant genetic traits since they act also in the presence of the homologous wild-type allele. However, the concept of a dominance of the transformed phenotype has been challenged by early experiments with somatic cell hybrids which showed that the fusion of normal and malignant cells may suppress the tumorigenic phenotype. The suppression or reversion of the malignant phenotype by the introduction of a normal chromosome into a tumor cell line has lent support to the idea that a family of cellular genes are coding for factors capable to interact with the cell-growth control machinery. These genes seem to reconstitute the normal control of cell growth even in the presence of an activated oncogene. In addition, a two-mutation model has been proposed to explain the epidemiological and clinical features of childhood cancers. According to the model, the development of these malignancies can be caused by the loss or inactivation of both alleles of cellular genes, as suggested by the somatic cell hybrid experiments where the function of the inactivated genes is restored by the contribution of those derived from the normal parental cells. This family of genes is designated as onco-suppressor genes since their product is necessary for the normal regulated cell growth and is lacking or inactivated in malignant cells. At gene level they should be considered as recessive genetic traits, since the tumor phenotype appears when both alleles of an onco-suppressor gene are inactivated. The mutations affecting their normal functions belong to the type "loss of function". The molecular analysis of retinoblastoma has led to the cloning and sequencing of the related onco-suppressor gene (RB gene) whose product displays the features of a gene-regulatory protein. In addition, a binding between the RB product and various viral onco-proteins (E1A, large T, E7) has been demonstrated, thus suggesting a mechanism of RB inactivation by which some DNA viruses can transform the host cell.(ABSTRACT TRUNCATED AT 400 WORDS)
自从在肿瘤细胞中鉴定并表征了通常控制细胞生长和分化的细胞基因(癌基因)的改变或激活形式以来,对多步骤致癌作用分子机制的分析在实验上变得可行。激活突变赋予癌基因产物新特性,因此应被视为功能获得性突变。此外,癌基因似乎表现为显性遗传性状,因为它们在同源野生型等位基因存在时也能发挥作用。然而,转化表型的显性概念受到了体细胞杂交早期实验的挑战,这些实验表明正常细胞与恶性细胞的融合可能会抑制致瘤表型。通过将一条正常染色体引入肿瘤细胞系来抑制或逆转恶性表型,这支持了这样一种观点,即一类细胞基因编码能够与细胞生长控制机制相互作用的因子。即使在存在激活的癌基因的情况下,这些基因似乎也能重建细胞生长的正常控制。此外,有人提出了一个双突变模型来解释儿童癌症的流行病学和临床特征。根据该模型,这些恶性肿瘤的发生可能是由于细胞基因的两个等位基因缺失或失活所致,体细胞杂交实验表明,失活基因的功能可通过来自正常亲代细胞的基因贡献而恢复,这支持了这一观点。这一类基因被称为肿瘤抑制基因,因为它们的产物对于正常调节的细胞生长是必需的,而在恶性细胞中则缺失或失活。在基因水平上,它们应被视为隐性遗传性状,因为当肿瘤抑制基因的两个等位基因都失活时才会出现肿瘤表型。影响其正常功能的突变属于“功能丧失”类型。视网膜母细胞瘤的分子分析导致了相关肿瘤抑制基因(RB基因)的克隆和测序,其产物具有基因调节蛋白的特征。此外,已证明RB产物与各种病毒癌蛋白(E1A、大T、E7)之间存在结合,从而提示了RB失活的一种机制,一些DNA病毒可通过这种机制转化宿主细胞。(摘要截短于400字)